Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: a requirement for stable antibody interactions.

FcγRs play a critical role in the immune response following recognition of invading particles and tumor associated antigens by circulating antibodies. In the present study we investigated the role of FcγR glycosylation in the IgG interaction and observed a stabilizing role for receptor N-glycans. We performed a complete glycan analysis of the recombinant FcγRs (FcγRIa, FcγRIIa, FcγRIIb, FcγRIIIa(Phe158/Val158), and FcγRIIIb) expressed in human cells and demonstrate that receptor glycosylation is complex and varied between receptors. We used surface plasmon resonance to establish binding patterns between rituximab and all receptors. Complex binding was observed for FcγRIa and FcγRIIIa. The IgG-FcγR interaction was further investigated using a combination of kinetic experiments and enzymatically deglycosylated FcγRIa and FcγRIIIa(Phe158/Val158) receptors in an attempt to determine the underlying binding mechanism. We observed that antibody binding levels decreased for deglycosylated receptors, and at the same time, binding kinetics were altered and showed a more rapid approach to steady state, followed by an increase in the antibody dissociation rate. Binding of rituximab to deglycosylated FcγRIIIa(Phe158) was now consistent with a 1:1 binding mechanism, while binding of rituximab to FcγRIIIa(Val158) remained heterogeneous. Kinetic data support a complex binding mechanism, involving heterogeneity in both antibody and receptor, where fucosylated and afucosylated antibody forms compete in receptor binding and in receptor molecules where heterogeneity in receptor glycosylation plays an important role. The exact nature of receptor glycans involved in IgG binding remains unclear and determination of rate and affinity constants are challenging. Here, the use of more extended competition experiments appear promising and suggest that it may be possible to determine dissociation rate constants for high affinity afucosylated antibodies without the need to purify or express such variants. The data described provide further insight into the complexity of the IgG-FcγR interaction and the influence of FcγR glycosylation.

[1]  C. Anderson,et al.  Phagocytosis mediated by three distinct Fc gamma receptor classes on human leukocytes , 1990, The Journal of experimental medicine.

[2]  R. Kimberly,et al.  Carbohydrates on human Fc gamma receptors. Interdependence of the classical IgG and nonclassical lectin-binding sites on human Fc gamma RIII expressed on neutrophils. , 1989, Journal of immunology.

[3]  C. Kallenberg,et al.  Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. , 1995, Arthritis and rheumatism.

[4]  P. Rudd,et al.  Separation of 2-aminobenzamide labeled glycans using hydrophilic interaction chromatography columns packed with 1.7 microm sorbent. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  Kazuhiro Masuda,et al.  Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans , 2011, Genes to cells : devoted to molecular & cellular mechanisms.

[6]  C. Fritsch,et al.  Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab , 2013, BioDrugs.

[7]  R. Cummings,et al.  Differential expression of LacdiNAc sequences (GalNAc beta 1-4GlcNAc-R) in glycoproteins synthesized by Chinese hamster ovary and human 293 cells. , 1997, Glycobiology.

[8]  R. Jefferis,et al.  IgG‐Fc‐mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation , 1998, Immunological reviews.

[9]  C. Sautès-Fridman,et al.  N-glycosylation profile of recombinant human soluble Fcγ receptor III , 2002 .

[10]  P. Katsamba,et al.  Analyzing a kinetic titration series using affinity biosensors. , 2006, Analytical biochemistry.

[11]  R. Kimberly,et al.  Antibodies to C1q in systemic lupus erythematosus: characteristics and relation to Fc gamma RIIA alleles. , 1997, Kidney international.

[12]  R. Dwek,et al.  "Internal residue loss": rearrangements occurring during the fragmentation of carbohydrates derivatized at the reducing terminus. , 2002, Analytical chemistry.

[13]  G. Broze,et al.  The asparagine-linked oligosaccharides on tissue factor pathway inhibitor terminate with SO4-4GalNAc beta 1, 4GlcNAc beta 1,2 Mana alpha. , 1992, The Journal of biological chemistry.

[14]  A. Kaubisch,et al.  Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. , 1987, Journal of immunology.

[15]  J. Peter-Katalinic,et al.  Cell type-specific and site directed N-glycosylation pattern of FcγRIIIa. , 2011, Journal of proteome research.

[16]  P. Umaña,et al.  The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. , 2006, The Journal of biological chemistry.

[17]  Kim Vo,et al.  Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. , 2011, Glycobiology.

[18]  M. Wormald,et al.  N-linked glycan structures of the human Fcγ receptors produced in NS0 cells. , 2013, Journal of proteome research.

[19]  P. Bruhns,et al.  Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. , 2009, Blood.

[20]  J. D. Young,et al.  The increase in intracellular free calcium associated with IgG gamma 2b/gamma 1 Fc receptor-ligand interactions: role in phagocytosis. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. H. van den Eijnden,et al.  Novel glycosylation routes for glycoproteins: the lacdiNAc pathway. , 1995, Biochemical Society transactions.

[22]  R. Kimberly,et al.  Fc gamma RIII expressed on cultured monocytes is a N-glycosylated transmembrane protein distinct from Fc gamma RIII expressed on natural killer cells. , 1990, Journal of immunology.

[23]  David I. Stuart,et al.  The Human Low Affinity Fcγ Receptors IIa, IIb, and III Bind IgG with Fast Kinetics and Distinct Thermodynamic Properties* , 2001, The Journal of Biological Chemistry.

[24]  Maria Allhorn,et al.  Human IgG/FcγR Interactions Are Modulated by Streptococcal IgG Glycan Hydrolysis , 2008, PloS one.

[25]  R. Karlsson,et al.  Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. , 1997, Journal of immunological methods.

[26]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[27]  Armin Ruf,et al.  Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose , 2011, Proceedings of the National Academy of Sciences.

[28]  S. Iida,et al.  The N-linked oligosaccharide at FcγRIIIa Asn-45: an inhibitory element for high FcγRIIIa binding affinity to IgG glycoforms lacking core fucosylation , 2008, Glycobiology.

[29]  I. Shimada,et al.  N-glycan structures of a recombinant mouse soluble Fcγ receptor II , 1998, Glycoconjugate Journal.

[30]  R. Kimberly,et al.  Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding. , 1997, Journal of immunology.

[31]  D. Blanset,et al.  A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies , 2010, Cancer Immunology and Immunotherapy.

[32]  R. Misaki,et al.  Jack bean α-mannosidase digestion profile of hybrid-type N-glycans: effect of reaction pH on substrate preference. , 2011, Biochimie.

[33]  P. Capel,et al.  Fcã Receptor Iia (Cd32) Heterogeneity In Patients With Recurrent Bacterial Respiratory Tract Infections , 1994 .

[34]  Louise Royle,et al.  Proposal for a standard system for drawing structural diagrams of N‐ and O‐linked carbohydrates and related compounds , 2009, Proteomics.

[35]  Chan Pl,et al.  Regulation of the immune response. V. An analysis of the function of the fc portion of antibody in suppression of an immune response with respect to interaction with components of the lymphoid system. , 1971 .

[36]  G. Weißhaar,et al.  The asparagine-linked oligosaccharides at individual glycosylation sites in human thyrotrophin. , 1992, Glycobiology.

[37]  R. Kimberly,et al.  A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. , 1997, The Journal of clinical investigation.

[38]  H. Nakanishi,et al.  Molecular Cloning and Characterization of a Novel Human β1,4-N-Acetylgalactosaminyltransferase, β4GalNAc-T3, Responsible for the Synthesis of N,N′-Diacetyllactosediamine, GalNAcβ1–4GlcNAc* , 2003, Journal of Biological Chemistry.

[39]  F. Rüker,et al.  Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab). , 2012, Archives of biochemistry and biophysics.

[40]  J. Martín,et al.  Involvement of Fcgamma receptor IIIA genotypes in susceptibility to rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[41]  Pauline M Rudd,et al.  Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. , 2006, Methods in molecular biology.

[42]  Y. Wada,et al.  Calculated two-dimensional sugar map of pyridylaminated oligosaccharides: elucidation of the jack bean alpha-mannosidase digestion pathway of Man9GlcNAc2. , 1991, Analytical biochemistry.